首页> 外文期刊>Molecular and Cellular Biology >Maximal serum stimulation of the c-fos serum response element requires both the serum response factor and a novel binding factor, SRE-binding protein.
【24h】

Maximal serum stimulation of the c-fos serum response element requires both the serum response factor and a novel binding factor, SRE-binding protein.

机译:c-fos血清反应元件的最大血清刺激需要血清反应因子和新型结合因子SRE结合蛋白。

获取原文
           

摘要

We have previously reported on the presence of a CArG motif at -100 in the Rous sarcoma virus long terminal repeat which binds an avian nuclear protein termed enhancer factor III (EFIII) (A. Boulden and L. Sealy, Virology 174:204-216, 1990). By all analyses, EFIII protein appears to be the avian homolog of the serum response factor (SRF). In this study, we identify a second CArG motif (EFIIIB) in the Rous sarcoma virus long terminal repeat enhancer at -162 and show only slightly lower binding affinity of the EFIII/SRF protein for this element in comparison with c-fos serum response element (SRE) and EFIII DNAs. Although all three elements bind the SRF with similar affinities, serum induction mediated by the c-fos SRE greatly exceeds that effected by the EFIII or EFIIIB sequence. We postulated that this difference in serum inducibility might result from binding of factors other than the SRF which occurs on the c-fos SRE but not on EFIII and EFIIIB sequences. Upon closer inspection of nuclear proteins which bind the c-fos SRE in chicken embryo fibroblast and NIH 3T3 nuclear extracts, we discovered another binding factor, SRE-binding protein (SRE BP), which fails to recognize EFIII DNA with high affinity. Competition analyses, methylation interference, and site-directed mutagenesis have determined that the SRE BP binding element overlaps and lies immediately 3' to the CArG box of the c-fos SRE. Mutation of the c-fos SRE so that it no longer binds SRE BP reduces serum inducibility to 33% of the wild-type level. Conversely, mutation of the EFIII sequence so that it binds SRE BP with high affinity results in a 400% increase in serum induction, with maximal stimulation equaling that of the c-fos SRE. We conclude that binding of both SRE BP and SRF is required for maximal serum induction. The SRE BP binding site coincides with the recently reported binding site for rNF-IL6 on the c-fos SRE. Nonetheless, we show that SRE BP is distinct from rNF-IL6, and identification of this novel factor is being pursued.
机译:我们以前曾报道过劳氏肉瘤病毒长末端重复序列中-100处存在CArG基序,该基序与被称为增强因子III(EFIII)的禽核蛋白结合(A. Boulden和L. Sealy,病毒学174:204-216 (1990年)。通过所有分析,EFIII蛋白似乎是血清反应因子(SRF)的禽同源物。在这项研究中,我们在劳斯肉瘤病毒长末端重复增强子中于-162处鉴定出第二个CArG基序(EFIIIB),并且与c-fos血清反应元件相比,仅显示出EFIII / SRF蛋白对该元件的结合亲和力略低(SRE)和EFIII DNA。尽管所有这三个元素以相似的亲和力结合SRF,但c-fos SRE介导的血清诱导作用大大超过了EFIII或EFIIIB序列的诱导作用。我们推测,血清可诱导性的这种差异可能是由c-fos SRE上而不是EFIII和EFIIIB序列上发生的SRF以外的其他因子的结合引起的。在仔细检查与鸡胚成纤维细胞和NIH 3T3核提取物中的c-fos SRE结合的核蛋白后,我们发现了另一种结合因子SRE结合蛋白(SRE BP),它无法以高亲和力识别EFIII DNA。竞争分析,甲基化干扰和定点诱变已确定SRE BP结合元件重叠并紧邻c-fos SRE的CArG盒3'。 c-fos SRE的突变使其不再与SRE结合BP将血清诱导性降低至野生型水平的33%。相反,EFIII序列的突变(使其以高亲和力结合SRE BP)导致血清诱导增加400%,最大刺激与c-fos SRE相等。我们得出结论,最大的血清诱导需要SRE BP和SRF的结合。 SRE BP结合位点与c-fos SRE上最近报道的rNF-IL6结合位点重合。尽管如此,我们显示SRE BP与rNF-IL6不同,并且正在寻求这一新因子的鉴定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号